In yesterday’s Wall Street session, ProKidney Corp (NASDAQ:PROK) shares traded at $1.86, up 5.68% from the previous session.
As of this writing, 6 analysts cover ProKidney Corp (NASDAQ:PROK). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $6.00, we find $8.00. Given the previous closing price of $1.76, this indicates a potential upside of 354.55 percent. PROK stock price is now -42.64% away from the 50-day moving average and -79.42% away from the 200-day moving average. The market capitalization of the company currently stands at $114.56M.
There are 2 analysts who have given it a hold rating, whereas 4 have given it a buy rating. Brokers who have rated the stock have averaged $9.60 as their price target over the next twelve months.
With the price target of $16, BTIG Research recently initiated with Buy rating for ProKidney Corp (NASDAQ: PROK).
In other news, Palihapitiya Chamath, Former 10% Owner sold 7,256,367 shares of the company’s stock on Nov 19. The stock was sold for $9,498,584 at an average price of $1.31. Upon completion of the transaction, the Former 10% Owner now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 17, 10% Owner Palihapitiya Chamath sold 258,400 shares of the business’s stock. A total of $308,400 was realized by selling the stock at an average price of $1.19. This leaves the insider owning 5,183,367 shares of the company worth $9.64 million. Insiders disposed of 10,788,928 shares of company stock worth roughly $20.07 million over the past 1 year. A total of 42.53% of the company’s stock is owned by insiders.
Tuesday morning saw ProKidney Corp (NASDAQ: PROK) opened at $1.8000. During the past 12 months, ProKidney Corp has had a low of $1.12 and a high of $14.19. The fifty day moving average price for PROK is $3.2426 and a two-hundred day moving average price translates $9.0378 for the stock.
The latest earnings results from ProKidney Corp (NASDAQ: PROK) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.18, missing analysts’ expectations of -$0.16 by -0.02. This compares to -$0.55 EPS in the same period last year. The company reported revenue of $46.62 million for the quarter, compared to $35.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 31.05 percent.
ProKidney Corp(PROK) Company Profile
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases. The company’s lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture that is in Phase I for REACT in patients with Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
